Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF - PubMed (original) (raw)
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
Victoria Emuss et al. Cancer Res. 2005.
Abstract
The protein kinase B-RAF is mutated in approximately 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.
Similar articles
- Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M. Ikenoue T, et al. Cancer Res. 2003 Dec 1;63(23):8132-7. Cancer Res. 2003. PMID: 14678966 - C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA, DeNicola GM, Winter SP, Tuveson DA. Karreth FA, et al. Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017. Mol Cell. 2009. PMID: 19917255 - Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H. Zebisch A, et al. Cancer Res. 2006 Apr 1;66(7):3401-8. doi: 10.1158/0008-5472.CAN-05-0115. Cancer Res. 2006. PMID: 16585161 - RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R Jr. Roskoski R Jr. Biochem Biophys Res Commun. 2010 Aug 27;399(3):313-7. doi: 10.1016/j.bbrc.2010.07.092. Epub 2010 Jul 30. Biochem Biophys Res Commun. 2010. PMID: 20674547 Review. - Raf: a strategic target for therapeutic development against cancer.
Beeram M, Patnaik A, Rowinsky EK. Beeram M, et al. J Clin Oncol. 2005 Sep 20;23(27):6771-90. doi: 10.1200/JCO.2005.08.036. J Clin Oncol. 2005. PMID: 16170185 Review.
Cited by
- Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Sen B, et al. Sci Transl Med. 2012 May 30;4(136):136ra70. doi: 10.1126/scitranslmed.3003513. Sci Transl Med. 2012. PMID: 22649091 Free PMC article. - Main roads to melanoma.
Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Palmieri G, et al. J Transl Med. 2009 Oct 14;7:86. doi: 10.1186/1479-5876-7-86. J Transl Med. 2009. PMID: 19828018 Free PMC article. Review. - Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Nucera C, et al. Oncologist. 2011;16(3):296-309. doi: 10.1634/theoncologist.2010-0317. Epub 2011 Feb 25. Oncologist. 2011. PMID: 21355020 Free PMC article. - Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Peng S, et al. Oncotarget. 2016 Jan 5;7(1):565-79. doi: 10.18632/oncotarget.6376. Oncotarget. 2016. PMID: 26623721 Free PMC article. - Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Eum KH, Ahn SK, Kang H, Lee M. Eum KH, et al. Mol Cell Biochem. 2013 Jan;372(1-2):65-74. doi: 10.1007/s11010-012-1446-0. Epub 2012 Sep 2. Mol Cell Biochem. 2013. PMID: 22941213
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous